Eton Pharmaceuticals, Inc. (ETON) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -5.8%, revenue growth 98.6% YoY, P/E 142.9. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $79.95M |
| Revenue (TTM) | $0.1B |
| Net Margin | -5.8% |
| Operating Margin (TTM) | 15.4% |
| Net Debt / EBITDA | 0.0 |
| Revenue Growth (YoY) | 98.6% |
| EPS Growth (YoY) | -520.0% |
| FCF Growth (YoY) | -8.8% |
| P/E Ratio | 142.9 |
| EV / EBITDA | 87.0 |
| Price / Book | 38.91 |
| Price / Sales | 17.17 |
| FCF Yield | 1.9% |
| Altman Z-Score | 15.16 (safe) |
| Piotroski F-Score | 5/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
ETON overview · ETON earnings · ETON KPIs · ETON documents · ETON ownership · ETON peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.